A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

This study has been completed.

First Received: April 3, 2003 Last Updated: January 25, 2007 History of Changes

Sponsored by:	DynPort Vaccine Company LLC, A CSC Company
Information provided by:	DynPort Vaccine Company LLC, A CSC Company
ClinicalTrials.gov Identifier:	NCT00057525

Purpose

This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel.

Condition	Intervention	Phase
Anthrax	Biological: Vaccine	Phase I

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study
Official Title:	A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Resource links provided by NLM:

MedlinePlus related topics: Anthrax

U.S. FDA Resources

Further study details as provided by DynPort Vaccine Company LLC, A CSC Company:

Estimated Enrollment:	70
Study Start Date:	April 2003
Estimated Study Completion Date:	April 2004

Detailed Description:

This is a safety study with an open-label part (2 groups), followed by a dose-ranging part evaluating safety and immunogenicity using a double-blind, sequential-group design with randomization and placebo-control within each of the 6 groups. Volunteers in each dose group will receive two IM injections at Day 0 and Month 1

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Volunteers are eligible for this study if they meet all the following criteria:

Citizens of the U.S.
Age 18 to 40 years.
For women, a negative serum pregnancy test will be required at study entry and within 24 hours prior to each vaccination, as well as verbal assurance that adequate birth control measures are applied prior to initial vaccination and for 3 months after the last vaccination.
Good health as determined by medical history, physical examination, and clinical judgment.
Normal Baseline Clinical Laboratory Values at screening including:
- Complete Blood Count (CBC) including:
- White Blood Cell Count: 3.8 -10.8
- Red Blood Cell Count (Mill/MCL)
- Male: 4.20 - 5.80
- Female: 3.80 - 5.10
- Hemoglobin (G/DL)
- Male: 13.2 - 17.1
- Female: 11.7 – 15.5
- Hematocrit (%)
- Male: 38.5- 50.0
- Female: 35.0 - 45.0
- Platelet Count: 140 – 440 (THOUS/MCL)
- Differential
- Urine dipstick for protein and blood: negative or trace. If either is ≥ 1+, obtain complete urinalysis (UA). If microscopic UA confirms evidence of hematuria or proteinuria ≥ 1+, the volunteer is ineligible.
- Negative serology for HIV infection (ELISA test).
- CPK within normal limits
- Hepatic Function Tests including AST, ALT, ALK PHOS.
- Total bilirubin, BUN, serum creatinine, serum electrolytes
Availability for at least 13 months of follow-up from the time of the screening visit.
Successful completion of the Test of Understanding defined as 90% correct with three opportunities to take test. Errors will be reviewed with volunteer after each test.
Commitment for trial participation and signature of the approved consent form.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057525

Locations

United States, Maryland
Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr
Rockville, Maryland, United States, 20850

Sponsors and Collaborators

DynPort Vaccine Company LLC, A CSC Company

Investigators

Principal Investigator:

Merlin L Robb, MD

Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr., Rockville, MD 20850

More Information

No publications provided

Study ID Numbers:	rPA-EC-02, Anthrax
Study First Received:	April 3, 2003
Last Updated:	January 25, 2007
ClinicalTrials.gov Identifier:	NCT00057525 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by DynPort Vaccine Company LLC, A CSC Company:

Anthrax

Study placed in the following topic categories:

Bacterial Infections
Gram-Positive Bacterial Infections
Anthrax
Healthy

Additional relevant MeSH terms:

Bacterial Infections
Gram-Positive Bacterial Infections
Bacillaceae Infections
Anthrax

ClinicalTrials.gov processed this record on July 02, 2009